Incyte (INCY) Stock Price
Incyte Price
Over the last 19 years Incyte grew revenue by 31.7% annually, reaching 5.14 B USD. Earnings per share have grown at 68.5% per year over the last 10 years. For Incyte, the net margin of 25% is down versus 31.8% a few years ago.
Incyte stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Incyte over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Incyte stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Incyte's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Incyte Price |
|---|
Incyte Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Incyte Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (B USD) |
| NET INCOME (B USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|
| 4.24 | 5.14 | 5.71 | 6.28 | 6.47 | 4.7 | 4.79 | 5.46 |
| 14.78 | 21.22 | 11.03 | 9.97 | 3.12 | -27.47 | 1.96 | 13.98 |
| 93.19 | 93.25 | 83.99 | 76.37 | 74.06 | 102.11 | 100.15 | 87.87 |
| 3.95 | 4.79 | 4.79 | 4.79 | 4.79 | 4.79 | 4.79 | 4.79 |
| 0.03 | 1.29 | 1.61 | 1.8 | 2.05 | 1 | 0.9 | 1.4 |
| -94.64 | 3,918.75 | 24.88 | 12.08 | 13.83 | -51.39 | -9.24 | 55.09 |
| 210.53 | 200.7 | 200.7 | 200.7 | 200.7 | 200.7 | 200.7 | 200.7 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Incyte generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Incyte retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Incyte's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Incyte has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Incyte's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Incyte stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Incyte Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Incyte business model & stock analysis
Incyte SWOT Analysis
Strengths
Incyte Corp holds a strong position in the market with its innovative products, allowing it to capture a significant market share and maintain a competitive edge over its rivals.
Incyte Corp invests heavily in research and development, resulting in a robust pipeline of novel drugs. This enables the company to introduce new and effective medications, driving growth and improving patient outcomes.
Weaknesses
Incyte Corp's revenue is heavily reliant on a few key products, which exposes the company to risks such as patent expiry, competition, and regulatory changes. Diversifying the product portfolio could mitigate this vulnerability.
Compared to larger pharmaceutical companies, Incyte Corp has a relatively smaller market presence. This limits its negotiating power, market reach, and ability to compete on a global scale. Expanding market presence should be a focus for sustained growth.
Opportunities
The increasing prevalence of cancer and the rising demand for more effective treatments present a significant growth opportunity for Incyte Corp. By leveraging its R&D capabilities, the company can develop innovative therapies to address unmet medical needs.
Expanding into untapped international markets allows Incyte Corp to access a larger patient population and tap into emerging economies. This can drive revenue growth and decrease dependency on any single market.
Threats
Incyte Corp operates in a highly competitive industry, where major pharmaceutical companies invest heavily in R&D. Increased competitive pressure can adversely impact market share, pricing, and profitability.
The pharmaceutical industry is subject to strict regulations and compliance requirements. Non-compliance or changes in regulations can lead to delays in product approvals, increased costs, and potential legal issues for Incyte Corp.
Incyte Eulerpool Fair Value
Incyte historical P/E ratio, EBIT multiple, and P/S ratio
Incyte annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Incyte shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Incyte Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/28/2026 | 1.47USD | 1.26 BUSD | 2026 Q1 |
| 4/27/2026 | 1.47USD | 1.26 BUSD | 2026 Q1 |
| 2/10/2026 | 1.97USD | 1.38 BUSD | 2025 Q4 |
| 2/9/2026 | 1.97USD | 1.38 BUSD | 2025 Q4 |
| 4/30/2024 | 0.83USD | 923.42 MUSD | 2024 Q1 |
| 2/5/2024 | 1.16USD | 1.02 BUSD | 2023 Q4 |
| 7/31/2023 | 0.83USD | 926.95 MUSD | 2023 Q2 |
| 5/1/2023 | 0.69USD | 838.62 MUSD | 2023 Q1 |
| 2/6/2023 | 0.59USD | 891.11 MUSD | 2022 Q4 |
| 11/1/2022 | 0.73USD | 855.29 MUSD | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Incyte stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Incyte shareholder structure
| % | Name |
|---|---|
15.31841% | |
9.98843% | |
7.27214% | |
5.8247% | |
4.92066% | |
4.08643% |
Incyte Executives and Management Board
Mr. Herve Hoppenot
(65)Director · since 2014
Dr. Pablo Cagnoni
(62)President - Research and Development
Dr. Steven Stein
(58)Executive Vice President, Chief Medical Officer
Mr. Julian Baker
(58)Independent Chairman of the Board
Dr. Edmund Harrigan
(72)Independent Director
Incyte Supply Chain
Frequently asked questions about Incyte
The business model of Incyte Corp revolves around discovering, developing, and commercializing novel medicines to address the needs of patients with serious diseases. As a leading biotechnology company, Incyte focuses on discovering and developing small molecule drugs that target specific biological pathways involved in diseases such as cancer and immune-inflammatory disorders. By leveraging its expertise in genomics and medicinal chemistry, Incyte aims to bring innovative treatments to market, improving patients' lives worldwide. Through collaborations and partnerships, Incyte also strives to expand its product portfolio and accelerate its pipeline of promising therapies.
Incyte stock
Incyte Ticker
Incyte FIGI
All fundamentals and in-depth analysis of Incyte
Our stock analysis for Incyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Incyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.